chrisvoncsefalvay/vaers-outcomes huggingface dataset:
PROTEIN IN URINE; BLOOD IN URINE; VOMITING; HEADACHE; ABDOMINAL PAIN; This spontaneous report received from a patient concerned a 60 year old female. The patient's height, and weight were not reported. The patient's concurrent conditions included type 2 diabetes, rheumatoid arthritis, systemic lupus erythematosus, obesity, stage 2 chronic kidney disease, and psoriatic arthritis. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 041A21A expiry: UNKNOWN) dose was not reported, administered on 08-APR-2021 for prophylactic vaccination.  Concomitant medications included nitrofurantoin for blood in urine, and protein in urine. On 11-APR-2021 04:00, the subject experienced abdominal pain. On 11-APR-2021 09:00, the subject experienced vomiting. On 11-APR-2021 09:00, the subject experienced headache. On 14-APR-2021, the subject experienced protein in urine. On 14-APR-2021, the subject experienced blood in urine. Laboratory data included: Urinalysis (NR: not provided) positive for blood, positive for protein. Laboratory data (dates unspecified) included: Lupus anticoagulant positive (NR: not provided) positive. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from abdominal pain on 12-APR-2021, was recovering from headache, and vomiting, and the outcome of protein in urine and blood in urine was not reported. This report was non-serious.
Information has been received from a physician concerning an 18 year old white female who on 27 Nov 2006 was vaccinated with Gardasil (lot number 653650/0641F). Concomitant therapy on 27 Nov 2006 included Fluvirin. On 01 Dec 2006 the patient experienced dizziness with walking or standing. On 02 Dec 2006 the patient experienced headache on top of her head. Subsequently, the patient recovered from dizziness with walking or standing and headache on top of her head. A prescription treatment was given for the experiences (not specified). Additional information is not expected.
Pain, redness, swelling to injection site Lt deltoid. Treated with Cephalexin and BENADRYL.
First dose August 27th 2020 and 2nd dose December 20th 2020; This case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too short in a 43-year-old female patient who received HAV (Havrix) (batch number KM72C, expiry date 18th June 2022) for prophylaxis.   Co-suspect products included hepatitis A vaccine pre-filled syringe device injection syringe for prophylaxis.   Previously administered products included Havrix (received 1st dose on 27th August 2020).   On 20th December 2020, the patient received the 2nd dose of Havrix and hepatitis A vaccine pre-filled syringe device. On 20th December 2020, unknown after receiving Havrix and hepatitis A vaccine pre-filled syringe device, the patient experienced drug dose administration interval too short. On an unknown date, the outcome of the drug dose administration interval too short was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.  Additional details were provided as follows: The pharmacist reported that the patient received 2nd dose of Havrix earlier than the recommended interval, which led to shortening of vaccine schedule. The reporter consented to follow up.
Almost immediately after injection, the patient stated she was dizzy. I had her sit down. She turned a bright shade of red, said she felt faint, tachycardic, short of breath, and was shaking. She was frightened. We called EMS and they came to the pharmacy.  She did not leave with them and elected to drive herself home. The episode passed after about 10 to 12 minutes.
This spontaneous report has been received from a medical assistant refers to a 54 year old female patient. On 19-JAN-2015 the patient was vaccinated with ZOSTAVAX (strength, dose, route and lot # not reported), lot # J012661, expiration date: 10-JAN-2015. No adverse effects reported. Additional information has been requested.
Pt develp blotches on lt leg where DTP was given; The day a/(6MAY91) blotches were red, raised & warm to touch & all around area of DTP & approx 3" from site; MD states this is allergic rxn;
Hypersensitive skin sensation beginning with underside of right forearm. Spread to right side of torso eventually presenting as a rash with pain.
within 5mins after shot back of her throat started to feel like they was swelling, numbness on left side of face, lips became swollen
pt recv vax & became ill 10 days p/vax;pt had a viral synd which devel into encephalitis & was hosp;pt then devel aplastic anemia & dx w/Dubowitz synd;pt had recurrence of aplastic anemia;pt died
Coughing up phlegm. Chest congestion. Starting 2 hours after administration.
received shot to early. Parents brought her back and staff went to check if it was time another nurse gave the vaccine in the drive through, Patient waited 30 mins with no issues and was allowed to go home.
pt recv 1st and 2nd dose of vax on 31may96 and 01jul95.  last menstrual period 24jul95, she became pregnant.  28sep96 pt devel URI;amniocentesis indicated a nl fetus;28APR96 pt gave birth to a nl female;
Swelling and erythema to vaccine site (left arm) noted several hours after vaccination. Resolving erythema without induration or tenderness noted by PMD on 9/11/03 at well child visit.
He got pneumonia, Required cephalosporin intramuscular injection, nebulizer every 8 hours, chest x-rays.
tested positive and had COVID; tested positive and had COVID; This is a spontaneous report from a non-contactable representative. This reported is for a female patient.   A female patient of an unspecified age received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Solution for injection, Lot/Batch number: unknown), via an unspecified route of administration on an unspecified date as dose number unknown, single for COVID-19 immunisation. The patient medical history and concomitant medications were not reported. The patient underwent lab test for COVID. Tested positive on an unspecified date. It was unknown if the patient received any other vaccines within 4 weeks prior to the COVID vaccine. It was reported that patient mentioned she had tested positive and had COVID, she also said she had been vaccinated, she assumed it was the Pfizer vaccine, but was not certain. The events were serious. It was unknown if treatment was taken. The outcome of the events was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
This spontaneous report as received from a physician's assistant refers to a patient of unknown age and gender. On 09-SEP-2015, the patient was vaccinated with an improperly stored dose of MMR II (lot # L003855 exp date 05-FEB-2017) (dose and route not reported). The temperature excursion was 53.8 F for 10.75 hours from 17-AUG-2015 to 06-NOV-2015. No adverse event was reported. This is one of several reports received from the same source. Additional information is not expected as all follow up information to complete the case was received.
after about 30 minutes, I started having a metallic taste in my mouth.  I was also experiencing soreness in left arm area.   After about an hour, the pain in my arm started to feel as though it was spreading to my left chest cavity area.  I then started to get chest pains in the left breast area to the armpit area, but not severe, just concerning.  After probably 70-80 minutes, I started feeling drowsy.  I continued to feel drowsy all evening and did not sleep well.  I woke up and could not return to sleep at 4:45am.  My normal waking time is 6:00am.  I had/have quite a bit of soreness in my arm, but nothing unbearable.  No signs of rash or inflammation around injection sight.  I am taking a sick day from work to relax and recover from loss of sleep.  The metallic taste persist, but only an annoyance and taste seems to be normal when eating or drinking.  A slight achiness in joints, but a cold front was also moving in, which can cause me to have the same effect.
Arthralgia, Fever, Fatigue, Injection site soreness, Itchiness @ injection site Narrative:
60 year-old patient presents for right deltoid and biceps pain, redness, itching and swelling which began several hours after receiving PNEUMOVAX in his right arm. He simultaneously received influenza vaccination in the left deltoid but did not experience any type of reaction.
In reference to the Shingrix 50 CG Injection taken on the morning of 04/25/20220, I just wanted to report side effects for others. It did not get to the point where I went to the hospital. If it had not felt better I would have called the doctor today 04/27/2020. Since the pharmacist had warned me of possible side effects, I waited to see if it would pass, which it did. Later in the afternoon on 04/25/2020 after receiving the vaccine, I became very tired and whole body ached, I slept quite a bit in the afternoon. My arm was super sore which I expected, but is still pretty sore today as of 04/27/2020. I did move my arm around as instructed, but that is not really a concern, I also on 04/25/2020 experienced tightness in chest and coughing. By 04/26/2020, the tightness in chest, coughing and body aches were worse. I ran a slight fever of 99.8 degrees, usually my temperature is 97.6 to 98. I ended up wearing a mask, it seemed to help with the coughing. I took some Tylenol and Niquil cough medicine and I was able to sleep several hours in the afternoon and then a good 8 hours that night. The next morning the symptoms subsided with just a minor cough left. Note also, this was my second dose, I did not have these side effects on the first dose, I remember my arm was sore a few days and I may have slept a bit. The pharmacist did say that the second dose would be more full and I may experience more side effects. This is not a complaint, I just merely wanted to pass on what I experienced so it may be helpful to others.
still her sore throat was going bad, didn't get better/sore throat had been going on for two weeks; her headaches were the same/She had a headache that didn't go away; her eyes sight, her vision sometimes was not clear/Her vision had also been affected. Sometimes she cannot see clearly; her lips looked like when had a high fever, which she hadn't and it's blue, the skin was going off/Her lips looked like she had a fever. Her lips were blue. Her lips were losing skin; her lips looked like when had a high fever, which she hadn't and it's blue, the skin was going off/Her lips looked like she had a fever. Her lips were blue. Her lips were losing skin; This is a spontaneous report from a contactable consumer (patient). A 68-year-old female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via unspecified route of administration on 22Jan2021 at single dose for COVID-19 immunization. The relevant medical history and concomitant medications were not reported. The patient stated that still her sore throat was going bad, didn't get better and her headaches were the same, her eyes sight, her vision sometimes was not clear and her lips looked like when had a high fever, which she hadn't and it's blue, the skin was going off and she didn't know. Her biggest concern was her headache and her sore throat. She called her Doctor and he said there was nothing that he can do to call for advice. She had been taking every 4 hours Tylenol and taking antiseptic for her sore throat which had helped her in numb that site and help her for like 1 hour-1 hour and a half but then it came back. She had side effects that were still active. The worst side effect was a sore throat. Her sore throat had been going on for two weeks at the time of the report. Sometimes it seemed like it was going to get better, and then it came back. Her vision had also been affected. Sometimes she cannot see clearly. She had a headache that didn't go away. Her lips looked like she had a fever. Her lips were blue. Her lips were losing skin. She had taken her temperature, and she didn't have a fever. The outcome of the events was not recovered.  Information about lot/batch number has been requested.
extreme fatigue, shivering, fever,  X 24 hours pain at injection site X 72 hours
Five days post vax, pt complained of entire body rash of large hives. Pt saw her primary care physician and was treated with antihistamine but hives continued for one week. No throat or face involvement.
Erythema, pain, edema at site. Use ice, Ibuprofen. PERCOCET as needed.
Pain, swelling at the site of injection 2-5 days after the injection. Blistering in the mouth and vagina 3-5 days after injections.
The vaccination hit the nerve.  Which I knew at the time, because it was immediately painful and I started saying, "Nerve, nerve, nerve!"  Now 4 hours on, I have pain and some weakness along my lower arm and into my pinky finger.
pt devel rash on 30NOV98 w/welts on chest;this rash & welts progressed to thighs, legs & today 1DEC98 to face;
Nasty headache which remained after acetaminohen/ibuprofen,  congestion,  fever,  felt like my hesd was on someone else's body, aloofness, etc.
Redness, bump; given diphenhydramine liquid, 12.5 mg/5 ml, 8 ml orally 3 times a day, 3 days.
Got up this am c/o hurting- left thigh with 5cm x 4 1/2 cm. Redness around DTaP injection site T98.5 Note: Shots given in legs- mother's request
This RN called to assist administering RN with client who c/o difficulty swallowing, dizziness, and warmth  about 10 min after vaccination. Client  had blow by face mask oxygen when this RN entered room, uncertain when applied. Client  was A&O X4, with clear lungs and "feeling better already when 1st set of vitals taken @ 10:35am( BP 126/88, HR 84). 10:45am client was able to drink water without difficulty  after oxygen taken off at 10:40am but c/o "warmth on right side of lungs" with no DOB, BP 122/82 and HR 70. 11:10am client  stated "heat moving around chest/diaphragm, just a warmth and denied tightness." Administering RN back to assess/monitor client, 11:15am BP122/82, HR 72 , lungs clear, client c/o flushing and client released home.
FATIGUE/FEELING REALLY TIRED; FEELING SLIGHTLY WARM; This spontaneous report received from a consumer concerned a male of unspecified age. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: UNKNOWN, expiry: UNKNOWN) dose was not reported, administered on 04-APR-2021 for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. On APR-2021, the subject experienced feeling slightly warm. On 05-APR-2021, the subject experienced fatigue/feeling really tired. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from fatigue/feeling really tired, and the outcome of feeling slightly warm was not reported. This report was non-serious.
Arms and legs felt like rubber; Paralyzed; This case was reported by a pharmacist via call center representative and described the occurrence of paralysis in a female patient who received Herpes zoster (Shingrix) (batch number E99E7, expiry date 11th May 2023) for prophylaxis.   On 2nd September 2021, the patient received Shingrix. On 2nd September 2021, less than a day after receiving Shingrix, the patient experienced paralysis (serious criteria GSK medically significant). On an unknown date, the patient experienced flaccidity. On an unknown date, the outcome of the paralysis and flaccidity were unknown.   It was unknown if the reporter considered the paralysis and flaccidity to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient received the Shingrix and was paralyzed. On an unknown date in 2021, less than 4 months after receiving the Shingrix, the patient's arms and legs felt like rubber. The reporter consented to follow up.
Bivalent vaccines have undergone several temperature excursions and may have been administered to patients; No adverse event; Bivalent vaccines have undergone several temperature excursions and have been administered to patient; This spontaneous case was reported by a nurse and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (Bivalent vaccines have undergone several temperature excursions and have been administered to patient), PRODUCT TEMPERATURE EXCURSION ISSUE (Bivalent vaccines have undergone several temperature excursions and may have been administered to patients) and NO ADVERSE EVENT (No adverse event) in a 50-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7146B) for COVID-19 prophylaxis.     No Medical History information was reported.    On 21-Sep-2022 at 1:59 PM, the patient received fourth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular) 1 dosage form. On 21-Sep-2022 at 1:59 PM, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Bivalent vaccines have undergone several temperature excursions and have been administered to patient). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Bivalent vaccines have undergone several temperature excursions and may have been administered to patients) and NO ADVERSE EVENT (No adverse event). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (Bivalent vaccines have undergone several temperature excursions and have been administered to patient), PRODUCT TEMPERATURE EXCURSION ISSUE (Bivalent vaccines have undergone several temperature excursions and may have been administered to patients) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for POOR QUALITY PRODUCT ADMINISTERED (Bivalent vaccines have undergone several temperature excursions and have been administered to patient) and PRODUCT TEMPERATURE EXCURSION ISSUE (Bivalent vaccines have undergone several temperature excursions and may have been administered to patients).    Patient received vaccine in deltoid. No concomitant product reported by the reporter.  Bivalent vaccines stored in the refrigerator that underwent several temperature excursions going back to August 2022. Patient received 0.5 of Bivalent vaccine No adverse reactions experienced by the patient. It was unknown if patient had ever been diagnosed or tested positive for COVID-19.  No treatment medication reported by the reporter.
Excelerated heart rate on numerous occasions starting in April, 2021 and included an emergency run by ambulance to Hospital in state. At that time heart rate was 167. I have had numerous tests run with no final diagnosis so far.
after receiving booster , 2 days later  developed severe burning and  tingling sensation in both legs/ including thighs and feet/ had neurology evaluation,  mri lumbal and cervical spine, and EMG study all tests came back normal symptoms start to subside 3 weeks after
After receiving his second dose, the patient reported having a seizure about 2 hours after his first dose.  He said the episode lasted about 4-5 minutes, and he was covered in sweat afterwards. He did not follow up with a physician because he does not have insurance. He also did not inform the pharmacy until later because he was afraid we would refuse to administer the second dose.
Patient awoke the morning of March 5th feeling weak, fatigued, and unsteady. He went to his primary care provider 5 days later on the 10th of March, as his symptoms were not improving. He told his PCP there that the past few days he was suffering from unsteady gait, walking around like hes "drunk", and bouncing off walls. It was thought his symptoms were caused by a low serum potassium value, so he was given a rx for potassium. 3 days later the patient presented to the emergency room where his problems persisted. He was still having trouble keeping balance when he walked around. One of the providers treating him reached out to neurology, who recommended that the patient be started on high dose steroids followed by a prednisone taper for tranverse myelitis, The patient was then admitted and treated at Hospital.
Redness, swelling, tenderness, warm to touch at site of injection.  Treatment-cold compress and BENADRYL.
At 1310 patient reported itchy hands that were red on the palms. BP 141/79, O2 at 98% and HR 113, hands were mottled and red, 50mg Benadryl given at 1312says se At 1316 BP was 125/80, HR 102 and O2 98%. Patient reports not issues with swallowing, no SOB, no dizziness or other issues.  At 1324 BP was 123/74, HR 99 and O2 98 At 1336, HR 97, BP 124/77, O2 97, patient feels less itchy and denies chest pain, SOB temp 98.0 Patient comfortable to go home
Also 2 weeks after 2nd vaccine antibodies at 62 & 2 weeks before 3rd vaccine were at 43.; This is a spontaneous report from a contactable consumer(patient).   A 63-years-old male patient received bnt162b2 (Pfizer COVID 19), dose 2 via an unspecified route of administration, administered in Arm Left on 30Mar2021 13:00 at his 63-years-old (Lot Number: ER8727) as dose 2, single for covid-19 immunisation.  Medical history included CLL(chronic lymphocytic leukaemia) 2013 23% residual , Low platelets (75-90), Bicuspid Aorta ascending aortic aneurysm. Concomitant medication included tadalafil (TADALAFIL). Historical Vaccine included first dose BNT162B2(DOSE 1, SINGLE, Lot No: EN6205) on 06Mar2021 01:00 PM at his 63-years-old, Location of injection was arm Left for covid-19 immunisation.  The patient experienced 2 weeks after 2nd vaccine antibodies at 62 & 2 weeks before 3rd vaccine were at 43 on an unspecified date which resulted in: Doctor or other healthcare professional office/clinic visit, Emergency room/department or urgent care, Hospitalization, Life threatening illness.  The patient was hospitalized from 27Oct2021 for 7 days.  He was admitted 27Oct2021 to Hospital 7 days & given IV antibiotics & daily Leukine injections to stimulate Neutrophils production. Outcome of event was recovered with sequelae.  Follow-up attempts are completed. No further information is expected.
limited appetite for various food; This is a spontaneous report from a contactable Other health care professional (Patient). A 62-years-old non-pregnant female patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection) (Batch/Lot Number: EW0186), via an unspecified route of administration on 14May2021 at 16:15 (age at vaccination 62-years-old) as dose 2, single for covid-19 immunization. Medical history included hypertension and patient was allergic to penicillin, statin, sulfa, latex and hypertension. Concomitant medications within two weeks included blood pressure medicine + statin. There were no other vaccine within 4 weeks. The patient did not had Covid prior vaccination and did not test for Covid post vaccination. The patient previously received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection), via an unspecified route of administration on 23Apr2021 at 16:30 (Batch/Lot Number: EW0172) as dose 1, single for covid-19 immunization and experienced hypersomnia. On 15May2021 at 13:00, after second vaccination, the patient experienced decreased appetite. It was reported that after second dose, the patient felt fine the next day until 1:00 pm and each day since. At 1:00 pm must lie down and rest for at least one hour. The patient had limited appetite for various foods which she usually eat, duration and intensity of these episodes is lessening (today was day 4 post inoculation) but still happened today. The patient did not received treatment for event. The patient was recovering from the event.